Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, China
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Our sub-categories
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Galderma Insights
    • Podcasts
  • Innovation
    • Bringing innovation to life
    • Partnerships
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors
  • Library
You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»
Results 126 - 130 of 162
Page 26 of 33
  1. Media
  2. Newsroom

Differin® Launches Clear90™ App, to Support People with Acne on Their Clear Skin Journey as Part of Third-Annual Retinoid Education Week

Leading Acne Brand, Differin, Continues to Educate Consumers About the Benefits of Acne-Fighting Retinoids and Introduces New App to Track Users’ Progress

 

  1. Media
  2. Newsroom

Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years

Next-Generation Treatment is First Option Studied and Proven Effective in Both Facial and Truncal Acne

  1. Media
  2. Newsroom

Galderma’s Restylane® Volyme™ demonstrates high effectiveness, satisfaction and a robust safety profile in Chinese patients with temple hollowing

  • Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 
  • Re
  1. Media
  2. Newsroom

New study reveals the impact of ‘hidden acne’ on quality of life

  • Around 60% of patients with facial acne also have truncal involvement1 however truncal acne is often overlooked in consultations2
  • This study, which examined the quality of life of >1300 acne sufferers with either facial acne alone or combined truncal and facial acne, reported that combined tr
  1. Media
  2. Newsroom

Fort Worth’s Galderma, Maker of Cetaphil, Presents the 4th Annual Wonder Run 5K and 1K Kids Waddle to Benefit Children’s Skin Disease Foundation

Cetaphil is Long-Term Provider of Products Essential to Children with Skin Diseases

 

Results 126 - 130 of 162
Page 26 of 33

Pagination

  • Previous page Previous Page
  • Next page Next Page
  1. Home
  2. Search results

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back